Pharmaceutical Business review

Innophos takes over AMT Labs

AMT is involved in manufacturing mineral ingredients essential to the human diet in the form of chelates as well as custom ingredients for the food, beverage, confectionary and nutraceutical industries.

Innophos said the acquisition complements the previous purchase of Kelatron in November 2011.

Innophos chairman and chief executive officer Randy Gress said the acquisition of AMT represents the second step in the company’s adjacency strategy to expand in product categories closely related to its existing specialty phosphate product line.

"AMT’s strengths are highly complementary to our new bioactive mineral ingredients business platform, providing high quality manufacturing facilities better able to support the future growth expected in this product range," Gress added.

"AMT has also been developing new market potential for its products which we expect will bring commercial successes in addition to the expected portfolio synergies of the combined business of AMT and Kelatron, which itself has performed strongly since its acquisition by Innophos last year."